{"doi":"10.32322/jhsm.1689929","title":"Relationship between spleen volume, spleen/liver SUVmax ratio, and percentage change and overall survival in patients undergoing immunotherapy","abstract":"<jats:p xml:lang=\"en\">Aims: This study aimed to investigate the pre- and post-treatment associations between spleen volume (SV), spleen/liver maximum standardized uptake value (SUVmax) ratio (SLR), and percent change (Δ) and overall survival (OS) in patients undergoing immunotherapy.\r\nMethods: This retrospective study included 89 patients who underwent 18F FDG PET/CT imaging before immunotherapy (baseline) and during post-treatment at 3 and 6 months. SV, spleen SUVmax, and liver SUVmax parameters were determined based on PET/CT images. Patients’ ages and date of mortality were recorded.  \r\nResults: In the present study, 52 (58.4%) were men, and the median OS was 17.7 (4-83) months. Furthermore, 63 out of 89 patients (70.8%) died during the study period. Baseline median SV value was 230 ml (47-1870). Baseline median SLR value was 0.80 (0.33-1.48). Median ΔSV1 at baseline and at 3 months post-treatment was -1.34 (-55.03-155.37). Percent change in SLR baseline and post-treatment (ΔSLR1) median was -0.52 (-48.39-121.02). Moreover, SLR1 had a sensitivity of 64.2% and specificity of 65.2% in detecting mortality with a cutoff value of &gt;0.80. For a SLR1 value of ≤0.79, median OS was 29.5 months and 1-3-year survival was 87/37%. SLR1 and SLR3 were independent prognostic factors for OS (p=0.003 and p=0.004, respectively). \r\nConclusion: SV values before and at 3 months post-immunotherapy and SLR values before and at 6 months post-treatment were prognostic factors for OS. Higher SLR1 and SLR3 values from 18F FDG PET/CT before and at 6 months post-treatment were independent prognostic factors and associated with shorter OS.</jats:p>","journal":"Journal of Health Sciences and Medicine","year":2025,"id":645535,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1680950,"name":"Özlem Beyler","orcid":"0000-0002-2032-8877","position":1,"is_corresponding":false},{"id":1680949,"name":"İhsan Kaplan","orcid":"0000-0002-5727-4702","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Relationship between spleen volume, spleen/liver SUVmax ratio, and percentage change and overall survival in patients undergoing immunotherapy","abstract":"<jats:p xml:lang=\"en\">Aims: This study aimed to investigate the pre- and post-treatment associations between spleen volume (SV), spleen/liver maximum standardized uptake value (SUVmax) ratio (SLR), and percent change (Δ) and overall survival (OS) in patients undergoing immunotherapy.\r\nMethods: This retrospective study included 89 patients who underwent 18F FDG PET/CT imaging before immunotherapy (baseline) and during post-treatment at 3 and 6 months. SV, spleen SUVmax, and liver SUVmax parameters were determined based on PET/CT images. Patients’ ages and date of mortality were recorded.  \r\nResults: In the present study, 52 (58.4%) were men, and the median OS was 17.7 (4-83) months. Furthermore, 63 out of 89 patients (70.8%) died during the study period. Baseline median SV value was 230 ml (47-1870). Baseline median SLR value was 0.80 (0.33-1.48). Median ΔSV1 at baseline and at 3 months post-treatment was -1.34 (-55.03-155.37). Percent change in SLR baseline and post-treatment (ΔSLR1) median was -0.52 (-48.39-121.02). Moreover, SLR1 had a sensitivity of 64.2% and specificity of 65.2% in detecting mortality with a cutoff value of &gt;0.80. For a SLR1 value of ≤0.79, median OS was 29.5 months and 1-3-year survival was 87/37%. SLR1 and SLR3 were independent prognostic factors for OS (p=0.003 and p=0.004, respectively). \r\nConclusion: SV values before and at 3 months post-immunotherapy and SLR values before and at 6 months post-treatment were prognostic factors for OS. Higher SLR1 and SLR3 values from 18F FDG PET/CT before and at 6 months post-treatment were independent prognostic factors and associated with shorter OS.</jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19910364","pmcid":null,"openalex_id":"https://openalex.org/W4413019251","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.25715601,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"https://dergipark.org.tr/en/download/article-file/4831126","host_type":"journal"},{"url":"https://dergipark.org.tr/en/download/article-file/4831126","host_type":"publisher"},{"url":"https://doi.org/10.32322/jhsm.1689929","host_type":"journal"},{"url":"https://dergipark.org.tr/en/pub/jhsm/article/1689929","host_type":"repository"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","Hepatocellular Carcinoma Treatment and Prognosis","Radiomics and Machine Learning in Medical Imaging"],"mesh_terms":[],"keywords":["Spleen","Medicine","Immunotherapy","Gastroenterology","Volume (thermodynamics)","Internal medicine","Immunology","Immune system"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-09T06:34:14.006264Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}